The Pridopidine Paradox in Huntington's Disease

被引：8

作者：

Reilmann, Ralf ^{[1
]}

机构：

[1] Univ Munster, Univ Clin Muenster UKM, Dept Neurol, Huntington Ctr, D-48149 Munster, Germany

来源：

MOVEMENT DISORDERS | 2013年 / 28卷 / 10期

关键词：

OBJECTIVE ASSESSMENT; END-POINTS; ACR16; (-)-OSU6162; PREMANIFEST; EFFICACY; MOBILITY; MOTOR;

D O I：

10.1002/mds.25559

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

引用

页码：1321 / 1324

页数：4

共 30 条

[1] Tapping linked to function and structure in premanifest and symptomatic Huntington disease [J].

Bechtel, N. ;

Scahill, R. I. ;

Rosas, H. D. ;

Acharya, T. ;

van den Bogaard, S. J. A. ;

Jauffret, C. ;

Say, M. J. ;

Sturrock, A. ;

Johnson, H. ;

Onorato, C. E. ;

Salat, D. H. ;

Durr, A. ;

Leavitt, B. R. ;

Roos, R. A. C. ;

Landwehrmeyer, G. B. ;

Langbehn, D. R. ;

Stout, J. C. ;

Tabrizi, S. J. ;

Reilmann, R. .

NEUROLOGY, 2010, 75 (24) :2150-2160

[2] Tapping in Huntington disease A path forward to preventive therapies? [J].

Biglan, Kevin M. .

NEUROLOGY, 2010, 75 (24) :2142-2143

[3] Physical therapy in Huntington's disease - toward objective assessments? [J].

Bohlen, S. ;

Ekwall, C. ;

Hellstrom, K. ;

Vesterlin, H. ;

Bjornefur, M. ;

Wiklund, L. ;

Reilmann, R. .

EUROPEAN JOURNAL OF NEUROLOGY, 2013, 20 (02) :389-393

[4] Mobility and falls in people with Huntington's disease [J].

Busse, M. E. ;

Wiles, C. M. ;

Rosser, A. E. .

JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2009, 80 (01) :88-90

[5] The dopaminergic stabilizers pridopidine (ACR16) and (-)-OSU6162 display dopamine D2 receptor antagonism and fast receptor dissociation properties [J].

Dyhring, Tino ;

Nielsen, Elsebet O. ;

Sonesson, Clas ;

Pettersson, Fredrik ;

Karlsson, Jonas ;

Svensson, Peder ;

Christophersen, Palle ;

Waters, Nicholas .

EUROPEAN JOURNAL OF PHARMACOLOGY, 2010, 628 (1-3) :19-26

[6] Pridopidine in treatment of Huntington's disease: beyond chorea? [J].

Feigin, Andrew .

LANCET NEUROLOGY, 2011, 10 (12) :1036-1037

[7] Pridopidine for the treatment of motor function in patients with Huntington's disease (MermaiHD): a phase 3, randomised, double-blind, placebo-controlled trial [J].

Garcia de Yebenes, Justo ;

Landwehrmeyer, Bernhard ;

Squitieri, Ferdinando ;

Reilmann, Ralf ;

Rosser, Anne ;

Barker, Roger A. ;

Saft, Carsten ;

Magnet, Markus K. ;

Sword, Alastair ;

Rembratt, Asa ;

Tedroff, Joakim .

LANCET NEUROLOGY, 2011, 10 (12) :1049-1057

[8] Analysis of the actions of the novel dopamine receptor-directed compounds (S)-OSU6162 and ACR16 at the D2 dopamine receptor [J].

Kara, Elodie ;

Lin, Hong ;

Svensson, Kjell ;

Johansson, Anette M. ;

Strange, Philip G. .

BRITISH JOURNAL OF PHARMACOLOGY, 2010, 161 (06) :1343-1350

[9] Unified Huntington's disease rating scale: Reliability and consistency [J].

Kieburtz, K ;

Penney, JB ;

Como, P ;

Ranen, N ;

Shoulson, I ;

Feigin, A ;

Abwender, D ;

Greenamyre, JT ;

Higgins, D ;

Marshall, FJ ;

Goldstein, J ;

Steinberg, K ;

Shih, C ;

Richard, I ;

Hickey, C ;

Zimmerman, C ;

Orme, C ;

Claude, K ;

Oakes, D ;

Sax, DS ;

Kim, A ;

Hersch, S ;

Jones, R ;

Auchus, A ;

Olsen, D ;

BisseyBlack, C ;

Rubin, A ;

Schwartz, R ;

Dubinsky, R ;

Mallonee, W ;

Gray, C ;

Godfrey, N ;

Suter, G ;

Shannon, KM ;

Stebbins, GT ;

Jaglin, JA ;

Marder, K ;

Taylor, S ;

Louis, E ;

Moskowitz, C ;

Thorne, D ;

Zubin, N ;

Wexler, N ;

Swenson, MR ;

Paulsen, J ;

Swerdlow, N ;

Albin, R ;

Wernette, C ;

Walker, F ;

Hunt, V .

MOVEMENT DISORDERS, 1996, 11 (02) :136-142

[10] A Randomized, Double-Blind, Placebo-Controlled Trial of Pridopidine in Huntington's Disease [J].

Kieburtz, Karl ;

McGarry, Andrew ;

McDermott, Michael ;

Kayson, Elise ;

Harrison, Madaline ;

Marder, Karen ;

Walker, Francis .

MOVEMENT DISORDERS, 2013, 28 (10) :1407-1415

← 1 2 3 →